Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 643.94

+2.5%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (3331)	7/14/2021 7:56:15 PM
From: CuttingEdge Bio	Read Replies (2) of 3557

Perhaps you misunderstood my comment. What I meant is that if the drug will not be successful UNLESS it can get to CNS, and the alnylam modality provides the means to do that, while an antibody does not, then the difference in profit sharing will not factor into that decision of which modality to pursue. The decision will be made based on what type of drug is needed for it to work sufficiently and be successful. Keeping 100% of US economics on a drug that won't work is not beneficial. They paid for access to this platform for a reason. So if they need to use it for a given program, they will. Or do you expect to just blow 800m on all this for no reason? To address the rest of your comment, the Sanofi partnership is not a flop because of the profit sharing or particularities of the deal in comparison to the one with Bayer. It's a flop because of products that didn't pan out commercially as they should/could have. Specifically, Praluent. The world I live in is called "reality."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next